Biotech & Pharma
Health Tech
Politics
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
By Dec. 17, 2021
Entrepreneurs at tech startups are likely to hear the Mark Zuckerberg adage that it’s important to “move fast and break things.” The concept that moving quickly to get ahead of competitors and get products in customer hands is appealing, but it doesn’t work across all industries.
Health care is one of the fields where moving too fast and “breaking” things could have disastrous results. Theranos is just one example where this type of philosophy was a horrendous idea. Lacking the R&D necessary to actually prove its product worked, the company delivered health test results to patients that were wholly inaccurate, for which it was rightfully sued. It takes just one misdiagnosis to destroy trust in a company’s product, especially when that result is as life changing as a positive (but false) result for an HIV antibody.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
health care
STAT+
This name will appear with your comment
There was an error saving your display name. Please check and try again.
By
By , and
advertisement
By Katie Palmer
By Adam Feuerstein
By Adam Feuerstein and Damian Garde
Reporting from the frontiers of health and medicine
source